Pyrukynd is EU approved as the first and only disease-modifying therapy for pyruvate kinase deficiency
Agios Pharmaceuticals, Inc. announced that the European Commission (EC) has granted marketing authorization for Pyrukynd for the treatment of PK deficiency in adult patients
Pyrukynd is a first-in-class, oral PK activator and the first approved disease-modifying therapy for patients in the EU with this rare, debilitating, lifelong hemolytic anemia.
“People with PK deficiency suffer from a lifetime of chronic anemia, associated complications and symptoms that can be detrimental to their work, family and social lives,” said Andreas Glenthøj, hematologist and head of the Danish Center for Hemoglobinopathies at Rigshospitalet, and associate proferukyndssor at the University of Copenhagen. “Pyrukynd offers new hope for this community, and I am honored to have contributed to the research efforts that enabled the approval of the first therapy for adults with PK deficiency in the EU.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.